US 12,214,007 B2
Fusion protein including BDNF
Hiroyuki Sonoda, Kobe (JP); and Kenichi Takahashi, Kobe (JP)
Assigned to JCR Pharmaceuticals Co., Ltd., Hyogo (JP)
Appl. No. 16/473,816
Filed by JCR Pharmaceuticals Co., Ltd., Hyogo (JP)
PCT Filed Dec. 26, 2017, PCT No. PCT/JP2017/046735
§ 371(c)(1), (2) Date Sep. 12, 2019,
PCT Pub. No. WO2018/124107, PCT Pub. Date Jul. 5, 2018.
Claims priority of application No. 2016-252147 (JP), filed on Dec. 26, 2016.
Prior Publication US 2020/0384061 A1, Dec. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 19/00 (2006.01); A61K 38/01 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61P 25/28 (2006.01); C07K 14/435 (2006.01); C07K 16/18 (2006.01); C07K 16/46 (2006.01); C12N 15/66 (2006.01)
CPC A61K 38/017 (2013.01) [A61K 38/185 (2013.01); C07K 16/18 (2013.01); C12N 15/66 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/62 (2013.01); C07K 2319/00 (2013.01)] 41 Claims
 
1. A fusion protein of human brain-derived neurotrophic factor (human BDNF) and an anti-human transferrin receptor antibody, selected from (1) or (2) below:
(1) the fusion protein wherein in a heavy chain variable region of the antibody,
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 66,
(b) CDR2 comprises the amino acid sequence of SEQ ID NO: 13,
(c) CDR3 comprises the amino acid sequence of SEQ ID NO: 15, and
(d) framework region 3 comprises the amino acid sequence of SEQ ID NO: 68,
wherein in a light chain variable region of the antibody,
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 6,
(b) CDR2 comprises the amino acid sequence of SEQ ID NO: 8, and
(c) CDR3 comprises the amino acid sequence of SEQ ID NO: 10, and
wherein the human BDNF binds to the N-terminus of the heavy chain of the antibody via a linker;
(2) the fusion protein wherein in a heavy chain variable region of the antibody,
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 67,
(b) CDR2 comprises the amino acid sequence of SEQ ID NO: 14,
(c) CDR3 comprises the amino acid sequence of SEQ ID NO: 16, and
(d) framework region 3 comprises the amino acid sequence of SEQ ID NO: 68, and
wherein in a light chain variable region of the antibody,
(a) CDR1 comprises the amino acid sequence of SEQ ID NO: 7,
(b) CDR2 comprises the amino acid sequence of SEQ ID NO: 9, and
(c) CDR3 comprises the amino acid sequence of SEQ ID NO: 10, and
wherein the human BDNF binds to the N-terminus of the heavy chain of the antibody via a linker.